The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

ST3GAL4  -  ST3 beta-galactoside alpha-2,3...

Homo sapiens

Synonyms: Alpha 2,3-ST 4, Alpha 2,3-sialyltransferase IV, Beta-galactoside alpha-2,3-sialyltransferase 4, CGS23, CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ST3GAL4

  • Clinical significance of ST3Gal IV expression in human renal cell carcinoma [1].
  • A multiplex reverse transcription-PCR method was used here to determine the expression of five sialyltransferases (ST3Gal III, ST6Gal I, ST3Gal IV, ST3Gal I, and ST3Gal II) in 49 patients surgically treated for locoregional breast cancer [2].
  • The other genes, Fuc-TIII, Fuc-TVI, and ST3Gal IV, which were most abundantly expressed in colorectal tissues, did not show significant up-regulation except in the poorly differentiated carcinomas [3].
  • Based on the levels of transcripts of the 12 enzymes together with the amounts of sialyl Lewis antigens, we concluded that Fuc-TIII, Fuc-TVI, and ST3Gal IV are mainly responsible for synthesis of the sialyl Lewis antigens in colon tissues, but are not responsible for the augmented expression of the antigens in colorectal cancers [3].
  • They had higher ST3Gal IV expression than patients without pulmonary hypertension (0.73 vs 0.29, p = 0.04) and a higher ST3Gal IV/ST6Gal I ratio than patients without pulmonary hypertension (1.03 vs 0.27, p = 0.03) and controls (1.03 vs 0.28, p = 0.02) [4].

High impact information on ST3GAL4


Chemical compound and disease context of ST3GAL4

  • Hematologic toxicity was similar for both treatments; however, the 5-FU plus STZ patients experienced more vomiting but acceptable renal toxicity [10].
  • FU/STZ improved survival compared with the doxorubicin-based regimen, suggesting that the combination should be considered to be an active regimen of therapy when chemotherapy is judged to be an option for selected patients with carcinoid tumors [11].
  • PATIENTS AND METHODS: Two hundred forty-nine patients with advanced carcinoid tumors were randomized to either doxorubicin with fluorouracil (FU/DOX) or streptozocin with fluorouracil (FU/STZ) [11].
  • Patients crossed over to the dacarbazine (DTIC) treatment after disease progression following first-line treatment (either FU/DOX or FU/STZ), and 73 patients were assigned to one of these three treatments based on their previous treatment or on abnormal baseline cardiac or renal function [11].
  • Relative to STZ-injected controls, P32/98-treated animals displayed increased weight gain (230%) and nutrient intake, decreased fed blood glucose ( approximately 26 vs. approximately 20 mmol/l, respectively), and a return of plasma insulin values toward normal (0.07 vs. 0.12 nmol/l, respectively) [12].

Biological context of ST3GAL4

  • These results indicate that down-regulation of ST3Gal IV mRNA may be one of the factors associated with the malignant progression of human RCC [1].
  • ST3Gal IV cDNA obtained by polymerase chain reaction from cDNA library of human RCC cell line ACHN was identical to STZ in nucleotide sequence [1].
  • Four genes, ST3Gal I, ST6Gal I, beta1,4GalT, and Core2 GnT, showed a tendency toward up-regulation, and a ST3Gal III gene showed a tendency toward down-regulation [3].
  • IL-1beta-induced sLeX expression on HuH-7 cells was suppressed by transfection of gene-specific small interference RNAs against FUT VI and ST3Gal IV but not against FUT IV and ST3Gal III [13].
  • Earlier work from our laboratory has shown that the respiratory burst and homotypic aggregation response in these cells induced by opsonized particles (serum-treated zymosan, STZ), is strongly enhanced after pretreatment (priming) with PAF [14].

Anatomical context of ST3GAL4

  • Characterization of two glycolipid: alpha 2-3sialyltransferases, SAT-3 (CMP-NeuAc:nLcOse4Cer alpha 2-3sialyltransferase) and SAT-4 (CMP-NeuAc:GgOse4Cer alpha 2-3sialyltransferase), from human colon carcinoma (Colo 205) cell line [15].
  • CONCLUSIONS: STZ mRNA and the enzyme itself are expressed in the basal layer of the corneal epithelium but are absent in the limbus [16].
  • In order to characterise the candidate alpha2,3-sialyltransferases necessary for biosynthesis of the selectin ligand SLe(x) and related antigens we have cloned and sequenced, from peripheral blood leukocytes of single individuals, various transcripts from the human ST3Gal III, IV and VI genes [17].
  • Low ST6Gal I expression associated with normal ST3Gal IV expression, resulting in a higher ST3Gal IV/ST6Gal I ratio, suggests an enhanced expression of Sialyl-LewisX at the surface of PBMC in SSc, and therefore an active interaction between activated endothelial cells and PBMC through the binding between E-selectin and Sialyl-LewisX [4].
  • In cremaster muscle venules with or without TNF-alpha treatment, L-selectin-dependent rolling was almost completely abolished in ST3Gal-IV(-/-) mice [18].

Associations of ST3GAL4 with chemical compounds


Regulatory relationships of ST3GAL4

  • Furthermore, the inflammatory cytokine TNF could enhance some alpha 2,3-ST and alpha 1,3/1,4-FT activities capable of generating E-selectin counter-receptors [20].

Other interactions of ST3GAL4


Analytical, diagnostic and therapeutic context of ST3GAL4

  • RESULTS: RT-PCR yielded cDNA of expected basepair length for STZ and ST3(Gal II [16].
  • The 6 cases that possessed almost the same levels of ST3Gal IV mRNA in primary tumor tissues as those in non-tumor kidneys showed favorable prognoses, as assessed by Kaplan-Meier curve [1].
  • Identification of nine alternatively spliced alpha2,3-sialyltransferase, ST3Gal IV, transcripts and analysis of their expression by RT-PCR and laser-induced fluorescent capillary electrophoresis (LIF-CE) in twenty-one human tissues [17].
  • RESULTS: In the randomized group, there was no difference between FU/DOX and FU/STZ in response rates (15.9% v 16%) and progression-free survival (4.5 v 5.3 months) [11].
  • The monoclonal antibodies also cross-reacted with the nucleocapsid proteins of simian (SA11), pig (OSU), bovine (NCDV and UK) and human (Wa and ST4) rotaviruses in an immunoblot ELISA reaction [24].


  1. Clinical significance of ST3Gal IV expression in human renal cell carcinoma. Saito, S., Yamashita, S., Endoh, M., Yamato, T., Hoshi, S., Ohyama, C., Watanabe, R., Ito, A., Satoh, M., Wada, T., Paulson, J.C., Arai, Y., Miyagi, T. Oncol. Rep. (2002) [Pubmed]
  2. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Recchi, M.A., Hebbar, M., Hornez, L., Harduin-Lepers, A., Peyrat, J.P., Delannoy, P. Cancer Res. (1998) [Pubmed]
  3. Up-regulation of a set of glycosyltransferase genes in human colorectal cancer. Kudo, T., Ikehara, Y., Togayachi, A., Morozumi, K., Watanabe, M., Nakamura, M., Nishihara, S., Narimatsu, H. Lab. Invest. (1998) [Pubmed]
  4. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in peripheral blood mononuclear cells in systemic sclerosis. Launay, D., Peyrat, J.P., Verdière, A., Hornez, L., Hatron, P.Y., Hachulla, E., Devulder, B., Hebbar, M. J. Rheumatol. (2004) [Pubmed]
  5. Mucopolysaccharidosis type IVA. N-acetylgalactosamine-6-sulfate sulfatase exonic point mutations in classical Morquio and mild cases. Fukuda, S., Tomatsu, S., Masue, M., Sukegawa, K., Iwata, H., Ogawa, T., Nakashima, Y., Hori, T., Yamagishi, A., Hanyu, Y. J. Clin. Invest. (1992) [Pubmed]
  6. LOS2, a genetic locus required for cold-responsive gene transcription encodes a bi-functional enolase. Lee, H., Guo, Y., Ohta, M., Xiong, L., Stevenson, B., Zhu, J.K. EMBO J. (2002) [Pubmed]
  7. Retroviral vector-mediated transfer of the tumor necrosis factor alpha gene into human cancer cells restores an apoptotic cell death program and induces a bystander-killing effect. Gillio Tos, A., Cignetti, A., Rovera, G., Foa, R. Blood (1996) [Pubmed]
  8. Growth and spread of human malignant T lymphoblasts in immunosuppressed nude mice: a model for meningeal leukemia. Cavallo, F., Forni, M., Riccardi, C., Soleti, A., Di Pierro, F., Forni, G. Blood (1992) [Pubmed]
  9. Inhibition of zymosan activation of human neutrophil oxidative metabolism by a mouse monoclonal antibody. Nauseef, W.M., Root, R.K., Newman, S.L., Malech, H.L. Blood (1983) [Pubmed]
  10. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. Engstrom, P.F., Lavin, P.T., Moertel, C.G., Folsch, E., Douglass, H.O. J. Clin. Oncol. (1984) [Pubmed]
  11. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Sun, W., Lipsitz, S., Catalano, P., Mailliard, J.A., Haller, D.G. J. Clin. Oncol. (2005) [Pubmed]
  12. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Pospisilik, J.A., Martin, J., Doty, T., Ehses, J.A., Pamir, N., Lynn, F.C., Piteau, S., Demuth, H.U., McIntosh, C.H., Pederson, R.A. Diabetes (2003) [Pubmed]
  13. Interleukin-1beta induces sialyl Lewis X on hepatocellular carcinoma HuH-7 cells via enhanced expression of ST3Gal IV and FUT VI gene. Higai, K., Miyazaki, N., Azuma, Y., Matsumoto, K. FEBS Lett. (2006) [Pubmed]
  14. Priming of human eosinophils by platelet-activating factor enhances the number of cells able to bind and respond to opsonized particles. Blom, M., Tool, A.T., Roos, D., Verhoeven, A.J. J. Immunol. (1992) [Pubmed]
  15. Characterization of two glycolipid: alpha 2-3sialyltransferases, SAT-3 (CMP-NeuAc:nLcOse4Cer alpha 2-3sialyltransferase) and SAT-4 (CMP-NeuAc:GgOse4Cer alpha 2-3sialyltransferase), from human colon carcinoma (Colo 205) cell line. Basu, S.S., Basu, M., Li, Z., Basu, S. Biochemistry (1996) [Pubmed]
  16. Differentiation-dependent expression of alpha-2,3-sialyltransferase in rabbit corneal epithelium. Matic, M., Petrov, I., Stegman, Z., Buku, A., Wolosin, J.M. Invest. Ophthalmol. Vis. Sci. (1998) [Pubmed]
  17. Identification of nine alternatively spliced alpha2,3-sialyltransferase, ST3Gal IV, transcripts and analysis of their expression by RT-PCR and laser-induced fluorescent capillary electrophoresis (LIF-CE) in twenty-one human tissues. Grahn, A., Larson, G. Glycoconj. J. (2001) [Pubmed]
  18. alpha2,3-Sialyltransferase-IV is essential for L-selectin ligand function in inflammation. Sperandio, M., Frommhold, D., Babushkina, I., Ellies, L.G., Olson, T.S., Smith, M.L., Fritzsching, B., Pauly, E., Smith, D.F., Nobiling, R., Linderkamp, O., Marth, J.D., Ley, K. Eur. J. Immunol. (2006) [Pubmed]
  19. Regulation of sialyltransferase expression by estradiol and 4-OH-tamoxifen in the human breast cancer cell MCF-7. Peyrat, J.P., Recchi, M.A., Hebbar, M., Pawlowski, V., Hornez, L., Dong-Lebouhris, X., Hondermarck, H., Harduin-Lepers, A., Delannoy, P. Mol. Cell Biol. Res. Commun. (2000) [Pubmed]
  20. Expression and function of alpha 2,3-sialyl- and alpha 1,3/1,4-fucosyltransferases in colon adenocarcinoma cell lines: role in synthesis of E-selectin counter-receptors. Majuri, M.L., Niemelä, R., Tiisala, S., Renkonen, O., Renkonen, R. Int. J. Cancer (1995) [Pubmed]
  21. Three genes that encode human beta-galactoside alpha 2,3-sialyltransferases. Structural analysis and chromosomal mapping studies. Chang, M.L., Eddy, R.L., Shows, T.B., Lau, J.T. Glycobiology (1995) [Pubmed]
  22. Molecular cloning of a novel alpha2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine structures on glycoproteins and glycolipids. Okajima, T., Fukumoto, S., Miyazaki, H., Ishida, H., Kiso, M., Furukawa, K., Urano, T., Furukawa, K. J. Biol. Chem. (1999) [Pubmed]
  23. Simultaneous core 2 beta1-->6N-acetylglucosaminyltransferase up-regulation and sialyl-Le(X) expression during activation of human tonsillar B lymphocytes. Nakamura, M., Ishida, T., Kikuchi, J., Furukawa, Y., Matsuda, M. FEBS Lett. (1999) [Pubmed]
  24. Biochemical evidence for the oligomeric arrangement of bovine rotavirus nucleocapsid protein and its possible significance in the immunogenicity of this protein. Sabara, M., Ready, K.F., Frenchick, P.J., Babiuk, L.A. J. Gen. Virol. (1987) [Pubmed]
WikiGenes - Universities